Company intelligence / Profile preview

Red Spruce Bioscience and Analytics

South San Francisco, California, USArestoreredspruce.org ↗

Ownership: Private
Development stage: Other

Overview

Spruce Biosciences is advancing two main programs. Tildacerfont, a CRF1 receptor antagonist for classic congenital adrenal hyperplasia and polycystic ovary syndrome, has completed multiple clinical trials. In April 2025, the company acquired tralesinidase alfa (TA-ERT), an enzyme replacement therapy for Sanfilippo Syndrome Type B; a Biologics License Application (BLA) submission to the FDA is anticipated in the first half of 2026. No commercial products yet.

Therapeutic areas: Rare DiseasesEndocrinology
Modalities: Enzyme replacement therapySmall molecule
Industry: Biotech

Partnerships

Kaken Pharmaceutical Co. Ltd. – licensing agreement for tildacerfont in Japan

Beyond the preview

Go deeper on Red Spruce Bioscience and Analytics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Red Spruce Bioscience and Analytics.

Explore the full profile